Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.

The use of march-in rights to target pricy drugs has been a controversial issue across several administrations.

Today’s headlines highlight critical developments in genetic medicine, global politics, and the latest updates from the ...

The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.

Vertex Pharmaceuticals won approval from the U.S. Food and Drug Administration for a non-opioid pain drug, clearing the way for the rollout of a product that has simultaneously sparked high hopes and ...

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...